Tabla de contenido
Publicidad
Se analizaron los siguientes niveles de interferencias endógenas y se encontró que eran
clínicamente irrelevantes: +342 μmol/l (+20,1 mg/dl) de bilirrubina no conjugada,
+342 μmol/l (+28,8 mg/dl) de bilirrubina conjugada, 109 mmHg de CO
+40 mmol/l (+244 mg/dl) de bicarbonato, pH >8,0, pH <6,8, Hct<10PCV, Hct>75PCV,
<6% de proteína, >9% de proteína, 1,4 mmol/l (23,5 mg/dl) de ácido úrico, 6,6 mmol/l
(74 mg/dl) de lactato, 131 mmHg de O
prolina, 1 μmol/l (0,01 mg/dl) de sarcosina y 42,9 mmol/l (258 mg/dl) de urea.
E. Referencias bibliográficas
P. D'Orazio, M.E. Meyerhoff, "Electrochemistry and Chemical Sensors", capítulo 4 de
1.
Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, cuarta edición, C.A.
Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St.Louis, 2006.
Rangos de referencia, tabla 56-1 en Tietz Textbook of Clinical Chemistry and Molecular
2.
Diagnostics, cuarta edición, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier
Saunders, St. Louis, 2006.
CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved
3.
Guideline, segunda edición, CLSI document EP09-A2 (ISBN 1-56238-472-4), CLSI, 940
West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 EE. UU., 2002.
CLSI. Interference Testing in Clinical Chemistry; Approved Guideline, CLSI document
4.
EP07-A2 (ISBN 1-56238-480-5), CLSI, 940 West Valley Road, Suite 1400, Wayne,
Pennsylvania 19087-1898 EE. UU., 2002.
CLSI. Evaluation of Precision in Clinical Chemistry Devices; Approved Guideline,
5.
segunda edición, CLSI document EP05-A2 (ISBN 1-56238-542-9), CLSI, 940 West
Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 EE. UU., 2004.
i-STAT 300, Abbott Point of Care Inc., 104 Windsor Center Drive, East Windsor, NJ
6.
08520, "i-STAT" es una marca comercial registrada de Abbott Laboratories.
CLSI. Evaluation of the Linearity of Quantitative Measurement Procedures; Approved
7.
Guideline, CLSI document EP06-A (ISBN 1-56238-498-8), CLSI, 940 West Valley Road,
Suite 1400, Wayne, Pennsylvania 19087-1898 EE. UU., 2003.
S. Whillier, J.E. Raftos, B. Chapman, P.W. Kuchel, "Role of N-acetylcysteine and cysteine
8.
in glutathione synthesis in human erythrocytes." Redox Report: Communications In
Free Radical Research, 2009, vol. 14, tercera edición, p. 115.
F. Ceriotti, J.C. Boyd, G Klein, J. Henny, J. Queralto, V. Kairisto, M. Panteghini, IFCC
9.
Committee on Reference Intervals and Decision Limits (C-RIDL), "Reference Intervals
for Serum Creatinine Concentrations: Assessment of Available Data for Global
Application", Clin. Chem. 54:3, p. 559-566, 2008.
Roche Cobas, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Suiza.
10.
Henry's Clinical Diagnosis and management by Laboratory Methods, Eds. McPherson &
11.
Pincus, 22
edición, Elsevier Sanders, 2011.
a
P. Ventura, R. Panini, M. C. Pasini, G. Scarpetta, G. Salvioli, "N-Acetyl-Cysteine Reduces
12.
Homocysteine Plasma Levels After Single Intravenous Adminstration by Increasing
Thiols Urinary Excretion." Pharmacological Research. Volumen 40, cuarta edición,
octubre de 1999, p. 345-350.
51004806 Rev: 07
22 mmHg de O
2,
Especificaciones generales de la tarjeta de análisis BGEM
15 mmHg de CO
2,
0,25 mmol/l (2,9 mg/dl) de
2,
2,
12-57
Publicidad
Tabla de contenido
